Corcept Therapeutics Inc (CORT)
22.48
-0.52
(-2.26%)
USD |
NASDAQ |
Apr 24, 16:00
22.50
+0.02
(+0.11%)
After-Hours: 20:00
Corcept Therapeutics Net Income (TTM): 106.14M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 106.14M |
| September 30, 2023 | 91.39M |
| June 30, 2023 | 94.62M |
| March 31, 2023 | 94.50M |
| December 31, 2022 | 101.42M |
| September 30, 2022 | 116.87M |
| June 30, 2022 | 112.73M |
| March 31, 2022 | 111.84M |
| December 31, 2021 | 112.51M |
| September 30, 2021 | 106.45M |
| June 30, 2021 | 97.61M |
| March 31, 2021 | 99.41M |
| December 31, 2020 | 106.01M |
| September 30, 2020 | 109.40M |
| June 30, 2020 | 114.11M |
| March 31, 2020 | 105.97M |
| December 31, 2019 | 94.18M |
| September 30, 2019 | 86.81M |
| June 30, 2019 | 78.22M |
| March 31, 2019 | 76.22M |
| December 31, 2018 | 75.41M |
| September 30, 2018 | 151.73M |
| June 30, 2018 | 147.74M |
| March 31, 2018 | 142.19M |
| December 31, 2017 | 129.12M |
| Date | Value |
|---|---|
| September 30, 2017 | 35.39M |
| June 30, 2017 | 24.22M |
| March 31, 2017 | 12.55M |
| December 31, 2016 | 8.14M |
| September 30, 2016 | 4.502M |
| June 30, 2016 | 1.316M |
| March 31, 2016 | -1.597M |
| December 31, 2015 | -6.408M |
| September 30, 2015 | -11.26M |
| June 30, 2015 | -16.67M |
| March 31, 2015 | -22.28M |
| December 31, 2014 | -31.38M |
| September 30, 2014 | -38.61M |
| June 30, 2014 | -43.51M |
| March 31, 2014 | -47.86M |
| December 31, 2013 | -46.01M |
| September 30, 2013 | -46.01M |
| June 30, 2013 | -43.40M |
| March 31, 2013 | -39.10M |
| December 31, 2012 | -38.05M |
| September 30, 2012 | -36.86M |
| June 30, 2012 | -35.00M |
| March 31, 2012 | -36.29M |
| December 31, 2011 | -32.35M |
| September 30, 2011 | -29.51M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
78.22M
Minimum
Jun 2019
116.87M
Maximum
Sep 2022
102.12M
Average
105.97M
Median
Mar 2020
Net Income (TTM) Benchmarks
| Ultragenyx Pharmaceutical Inc | -606.64M |
| Alnylam Pharmaceuticals Inc | -440.24M |
| Catalyst Pharmaceuticals Inc | 71.41M |
| United Therapeutics Corp | 984.80M |
| XOMA Corp | -40.83M |